No quarterly revenue total was found in Phio Pharmaceuticals Corp's SEC filings.
Phio Pharmaceuticals Corp (PHIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$2.3 million.
Revenue
—
Net income
$-4.16M
-73.9% vs year-ago quarter
Operating cash flow
$-2.28M
-9.4% vs year-ago quarter
Free cash flow
$-2.28M
-9.0% vs year-ago quarter
EPS
$-0.45
-9.8% vs prior quarter
Dividend per share
None
Shares outstanding
11.95M
+11.0% vs year-ago quarter
Net cash
$5.38M
Q4 FY2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PHIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- King Of Prussia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1533040
- Former names
- RXi Pharmaceuticals Corp (until Nov 14, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.3M | -$4.3M | -$4.2M | -$2.5M | -$2.5M |
| Net income | -$4.2M | -$4.1M | -$4.0M | -$2.4M | -$2.4M |
| Operating cash flow | -$2.3M | -$4.0M | -$4.0M | -$2.1M | -$2.1M |
| Free cash flow | -$2.3M | -$4.0M | -$4.0M | -$2.1M | -$2.1M |
| Total assets | $11.3M | $14.3M | $17.4M | $21.5M | $11.5M |
| Total liabilities | $2.7M | $1.7M | $950,000 | $1.3M | $1.7M |
| Stockholders' equity | $8.6M | $12.6M | $16.5M | $20.1M | $9.8M |
| Cash and investments | $10.6M | $13.0M | $17.0M | $21.0M | $10.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| ARS | Annual report to shareholders | Aug 14, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 892 Phio Pharmaceuticals Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.